Navigation Links
Data on SEEK's Novel Immunotherapy for HIV Published in Virology Journal
Date:4/16/2013

LONDON, April 16, 2013 /PRNewswire/ --

 Antibody Treatment for HIV

SEEK, a privately-owned UK drug discovery group, announces that pre-clinical results on its HIV immunotherapy have been published in the peer-reviewed journal Virology Journal.  

SEEK's HIV immunotherapy triggers the immune system's cellular and antibody responses to selectively identify and kill HIV infected cells. The most exciting aspect of this therapy is that it directs the immune system towards short highly conserved regions of proteins produced by most circulating HIV strains. The triggered immune responses are highly effective both independently and in combination.

This opens up developing the antibody response into a monoclonal based therapy for treating HIV.

Monoclonal antibodies have revolutionised the treatment of cancer by improving outcomes and survival. In HIV/AIDS there is new interest in these products, as shown by the recent work of Duke University (USA) in developing a monoclonal antibody that prevents the virus from infecting cells. A monoclonal antibody capable of killing HIV-infected cells (potentially curative effect) would represent a radical new development in HIV therapy, which to this day relies on slowing down the virus rate of growth rather than in killing the cells that harbour it.  

By targeting a HIV component that is found only in infected cells and never in healthy cells, such monoclonal antibody therapy offers the potential of high specificity, reduced frequency of administration and minimal side-effects. This would represent a significant improvement over current anti-HIV drugs which require daily treatment and are associated with significant side effects.

Commenting on today's announcement, Gregory Stoloff , CEO of SEEK Group, said: "It is  very exciting to be at the forefront of this new approach w
'/>"/>

SOURCE SEEK
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Searcy Denney Scarola Barnhart & Shipley PA Seeks Damages Caused by Recalled Product
2. American Academy of Pain Medicine Reacts to PROP Petition to the FDA that Seeks to Limit Pain Medications for Legitimate Noncancer Pain Sufferers
3. $1,000,000 Global B.R.A.I.N. Prize Seeks Applicants
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
6. Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies
7. Scripps Doctors Study Novel New Device to Diagnose Irregular Heart Beat
8. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
9. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
10. New Data Support Role of Prometheus Laboratories Novel Assay in Optimizing IBD Treatment Management
11. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. (OTC ... U.S. provisional patent application concerning composition of matter, biological ... targeted tumor cell death.  This patent ... double stranded RNA molecules (VSRNAs) which interfere with the ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... HARBIN, China, Oct. 25, 2011 /PRNewswire-Asia/ -- China Botanic ... Botanic" or the "Company"), a developer, manufacturer and distributor ... in China, today announced that the Company has recently ... in the field of Traditional Chinese Medicine (TCM) and ...
... 25, 2011 Merz Pharmaceuticals, LLC, today announced that ... profiles of Xeomin® (incobotulinumtoxinA), a botulinum toxin type A ... (eyelid spasms) will be presented at the 115th Annual ... Orlando, Fla. These data include an extension ...
Cached Medicine Technology:China Botanic Hosts Technical Exchange for Industry Research Experts 2China Botanic Hosts Technical Exchange for Industry Research Experts 3Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 2Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 3Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 4Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 5Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 6Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 7Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 8
(Date:4/24/2014)... corresponding terminology, and the relevance of palliation in ... on randomized controlled trials (RCTs). This is the ... for Quality and Efficiency in Health Care (IQWiG), ... , Together with external experts, IQWiG analysed studies ... cancer, malignant melanoma, and pancreatic cancer. For this ...
(Date:4/24/2014)... Dartmouth has been awarded one of 30 grants ... a Lead Academic Participating Site in its new ... are a select groups of investigators charged with distributing ... groups., The NCTN grant system reflects recommendations from a ... operations to achieve four goals:, Faster design, ...
(Date:4/23/2014)... Massachusetts General Hospital (MGH) investigators may lead to greater ... serious medical problem use of fecal material from ... Clostridium difficile ( C. difficile ) bacteria. ... journal Clinical Infectious Diseases , the researchers report ... unrelated to patients was as successful in curing recurrent ...
(Date:4/23/2014)... John J. O,Shea, M.D., scientific director at the National ... has been named the 2014 recipient of the Ross ... peer-reviewed, open-access journal Molecular Medicine . The award ... York Academy of Sciences in Manhattan, followed by scientific ... is part of the National Institutes of Health. , ...
(Date:4/23/2014)... Purdue University researchers have identified an important enzyme pathway ... or too few chromosomes, a condition that has been ... Hall, associate professor of biochemistry, found that near the ... an enzyme that ensures any breaks in DNA are ... the genome to daughter cells. This process helps safeguard ...
Breaking Medicine News(10 mins):Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2
... Texas, Feb. 12 Benjamin M. Cutler, ... Inc. (USHEALTH), a leading,national health insurer providing ... self-employed, announced today the promotion of Konrad ... Officer. In this,expanded role, Kober will oversee ...
... 7 Million Shares Shorted Since March 2006 According to ... ... BioElectronics,Corporation (Pink Sheets: BIEL) announced today that BUYINS.NET, http://www.buyins.net, ... sale data to February 2008. From March 2006 to,February 2008 ...
... a set of cues that we then use to make ... service or more expensive candles smell better. However, this set ... learn and recognize other real, positive qualities that are indicated ... April issue of the Journal of Consumer Research. , ...
... celebrities and,socialites have flocked to France for their ... and urban dwellers alike have,to go no further ... oral,care., (Photo: http://www.newscom.com/cgi-bin/prnh/20080212/LATU026 ), Elgydium(R), ... three,decades, has been available in the U.S. on ...
... Su Salud. Su Voz., Campaign to Address Lack of Public Awareness ... to File Medicare Quality of Care Complaints, ... join leaders of health care organizations and senior,groups, along with public ... Salud. Su Voz. Partnership to educate Latino,seniors about their right to ...
... DENVER, Feb. 12 PSI, a leading provider ... today the,signing of a contract with the Ohio ... delivering new hire reporting services for the State ... The new contract will run,for an initial period ...
Cached Medicine News:Health News:USHEALTH Group Announces Appointment of Executive Vice President 2Health News:BioElectronics Corporation (BIEL) SqueezeTrigger Price is $0.11 2Health News:BioElectronics Corporation (BIEL) SqueezeTrigger Price is $0.11 3Health News:BioElectronics Corporation (BIEL) SqueezeTrigger Price is $0.11 4Health News:BioElectronics Corporation (BIEL) SqueezeTrigger Price is $0.11 5Health News:BioElectronics Corporation (BIEL) SqueezeTrigger Price is $0.11 6Health News:Old dogs: Prior knowledge affects how consumers accept new information 2Health News:A Favorite in France, Elgydium(R) Toothpaste Makes Entrance Into the U.S. Market 2Health News:Milly Quezada, 'Queen of Merengue,' to Launch Partnership to Educate Latino Seniors About Health Care Rights 2Health News:Milly Quezada, 'Queen of Merengue,' to Launch Partnership to Educate Latino Seniors About Health Care Rights 3Health News:Ohio Selects Policy Studies Inc. (PSI) to Continue Operating Its New Hire Reporting Program 2
... Multi frequency and multigate ... detection and fitted with ... tests for hemodynamic evaluation. ... as well for routine ...
The Spencer Technologies PMD 100 (TCD 100M) is the worlds first stand-alone digital transcranial doppler system....
Swiss Watchmaker Forceps, 4" extra-long precision ground points....
The vertebral body replacement (VBR) is used for the anterior thoracic and lumbar spine. It is intended for use in the thoracic and lumbar spine to replace a collapsed, damaged, or unstable vertebral...
Medicine Products: